Twist Bioscience Corporation (NASDAQ:TWST) Shares Sold by XTX Topco Ltd

Key Points

• XTX Topco Ltd has reduced its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 57.3%, selling 20,302 shares and now owning 15,144 shares worth approximately $595,000.
• Twist Bioscience's stock has dropped by 8.9%, with current trading around $27.52, while analysts have mixed ratings and varying price targets for the stock.
• The company reported earnings of ($0.47) per share for the last quarter, surpassing analysts' estimates, with a total revenue of $96.06 million.

XTX Topco Ltd trimmed its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 57.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,144 shares of the company's stock after selling 20,302 shares during the period. XTX Topco Ltd's holdings in Twist Bioscience were worth $595,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Versant Capital Management Inc raised its holdings in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after buying an additional 580 shares during the last quarter. GAMMA Investing LLC increased its stake in Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after buying an additional 303 shares during the period. Banque Transatlantique SA purchased a new position in Twist Bioscience during the 4th quarter worth $43,000. GF Fund Management CO. LTD. acquired a new stake in shares of Twist Bioscience in the 4th quarter worth $58,000. Finally, Pallas Capital Advisors LLC purchased a new stake in shares of Twist Bioscience in the first quarter valued at about $201,000.

Insider Activity

In other news, CEO Emily M. Leproust sold 2,802 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $83,359.50. Following the sale, the chief executive officer owned 649,630 shares in the company, valued at $19,326,492.50. This trade represents a 0.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Patrick John Finn sold 1,877 shares of the company's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $55,840.75. Following the completion of the transaction, the chief operating officer owned 240,783 shares of the company's stock, valued at $7,163,294.25. This trade represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,109 shares of company stock valued at $425,962. Company insiders own 3.01% of the company's stock.

Twist Bioscience Trading Up 2.6%

Shares of TWST stock traded up $0.64 during trading hours on Friday, hitting $25.64. 1,968,799 shares of the company were exchanged, compared to its average volume of 1,144,916. The company has a quick ratio of 4.24, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.55 billion, a PE ratio of -17.68 and a beta of 2.36. Twist Bioscience Corporation has a 1 year low of $24.28 and a 1 year high of $55.33. The firm has a fifty day moving average of $34.55 and a 200 day moving average of $38.26.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. The company had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on TWST shares. The Goldman Sachs Group reduced their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Barclays cut their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Evercore ISI set a $46.00 price objective on Twist Bioscience in a research report on Monday. Finally, Robert W. Baird reduced their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $49.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.